ARTIFICIAL INTELLIGENCE
Quantifying the value of AI workflows in real-world laboratories
Quest Diagnostics commissioned a feasibility study in conjunction with Proscia and Ibex Medical Analytics in order to quantify the value of digital pathology and artificial intelligence workflows in a real-world diagnostic laboratory. Pathology in Practice presents an extract of the report.
Digital pathology (DP) shifts the diagnostic process from microscope to whole-slide image, unlocking insights previously unseen by the human eye to realise the promise of precision medicine. It also drives powerful efficiency gains that are helping laboratories to overcome a range of systemic challenges. Diagnostic artificial intelligence (AI) tools can be embedded into DP workflows. Numerous studies have demonstrated AI’s potential to improve diagnostic accuracy, save time, and support pathologists in their decision making, for example, by performing sophisticated image analysis and computer-aided diagnosis.1
DP and AI
technologies have enormous potential to impact the pathologists’ experience and overall job satisfaction, while delivering economic and operational returns. To meet growing demand, Quest collaborated with Proscia, an industry- leading enterprise digital pathology platform provider, and Ibex Medical Analytics (Ibex), a leading provider of AI-powered diagnostics for pathology, to run a feasibility study of their networked pathology solution in one of its laboratories. Quest wanted to translate the general findings of the study to understand how these technologies impact laboratory operations and their effects in a large diagnostic laboratory setting.
Quest ran a feasibility study of Proscia and Ibex’s networked pathology solution in one of its laboratories to understand how these technologies impacted operations in a large diagnostic laboratory setting.
WWW.PATHOLOGYINPRACTICE.COM AUGUST 2024
The study Quest, Proscia, and Ibex opted to have the study focus on prostate tissue captured using core needle biopsies (PCNBs). Prostate cancer is the second most commonly occurring cancer in men, with more than 1.4 million new cases annually. PCNBs are routinely used by physicians to test patients for cancer and ensure accurate, timely diagnosis,
35
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
